BenevolentAI is the global leader in the development and application of artificial intelligence (“AI”) for scientific innovation. We aim to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.
Our team of technologists, AI researchers, and scientists builds and applies AI to the entire drug discovery and development process. The technology unlocks what is not known by creating new ideas based on established facts to provide a different understanding of disease, which leads to inventive steps and real insights that drive the development of new medicines and treatments.
Total Funding: $292M
Funding Stage: Series F
Business Stage: N/A
Market: B2B
Company Size: 251 to 500
Founded: 2013
Dec 2020
- Joanna Shields Speaks At The Global Partnership On Artificial Intelligence
Dec 2020
- BenevolentAI Wins Innovation Award At 2020 Scrip Awards
Dec 2020
- BenevolentAI Wins Innovation Award At 2020 Scrip Awards
Feb 2020
- BenevolentAI Announces Scientific Collaboration With UC San Diego To Investigate Cerebral Cavernous Malformations
AI Scientist
New York, New York
Machine Learning Engineer
New York, New York
Senior AI Scientist
New York, New York
Lead AI Scientist
London, London
Senior Bioinformatics Data Scientist
New York, New York
